10.docx

**Prototype: exenatide (Byetta) ** - **Category: **Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, Incretin Mimetic (Non-insulin Injectable)  - **Primary Function: **GLP-1 receptor agonists, also known as incretin mimetics, replicate the effects of the incretin hormone GLP-1, re...

**Prototype: exenatide (Byetta) ** - **Category: **Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, Incretin Mimetic (Non-insulin Injectable)  - **Primary Function: **GLP-1 receptor agonists, also known as incretin mimetics, replicate the effects of the incretin hormone GLP-1, released from the gastrointestinal tract cells after a meal to help control blood glucose levels. They can be used alone or in combination with other medications for diabetes.  - **Unique Features: **GLP-1 receptor agonists are non-insulin injectable medications injected subcutaneously. They have also recently been studied and prescribed for weight management in clients without diabetes due to their ability to decrease food consumption, appetite, and hinger, while increasing sensations of fullness and satiety.  - **Example drugs in this class:** - Dulaglutide (Trulicity) - Exenatide extended release (Bydureon bcise) - Exenatide (Byetta) - Semaglutide (Ozempic) - Liraglutide (Victoza, Saxenda) - Lixisenatide (Adlyxin) - Semaglutide (Rybelsus)